Business Wire·Nov 9, 2026, 7:00 AM ET

Ionis reports third quarter 2026 financial results and highlights progress on key programs

IONS

Ionis Pharmaceuticals reported third-quarter 2026 total revenue of $243 million, a 55% increase year-over-year, with nine-month revenue reaching $757 million, a 64% increase.
TRYNGOLZA 2026 product sales guidance was lowered to approximately $50 million due to a more gradual launch ramp than anticipated, reflecting early dynamics in establishing a new treatment paradigm.
DAWNZERA launch momentum continued, with $37 million in Q3 sales, and the company reaffirmed its 2026 product revenue guidance of $110–120 million.
ZANVASTRO, the first approved medicine for Alexander disease, commenced its first independent neurology launch with the first patients dosed.
The company reaffirmed its 2026 total revenue guidance of $875–900 million, operating loss guidance, and cash guidance of over $1.6 billion.
Operating expenses for the nine months ended September 30, 2026, were $1.1 billion, driven by investments in commercialization efforts for TRYNGOLZA, DAWNZERA, and ZANVASTRO.
Ionis ended the third quarter with $1.9 billion in cash, cash equivalents, and short-term investments, down from $2.7 billion at year-end 2025 due to convertible note repayment.
SPINRAZA generated $69 million in royalty revenue in Q3 2026, while WAINUA contributed $7 million in royalty revenue.
HIBSAGO received approvals in the U.S., Japan, and Canada, with regulatory reviews ongoing in the EU and China.
Positive Phase 3 results were presented for Sefaxersen in IgAN and Ulefnersen in FUS-ALS, with data to be shared with health authorities.
Obudanersen Phase 3 enrollment for Angelman syndrome was completed, with data expected in the second half of 2027.
FCS launch for TRYNGOLZA is underway in Europe following a positive CHMP opinion, with a final approval decision expected in Q4 2026.
Management will host a conference call on November 9, 2026, to discuss the third-quarter results.